Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This first phase of a two-phase study involves three components:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Component 1 | Existing linkage to care protocols will be obtained from the 15 sites. This component does not involve study subjects. | ||
| Component 2 | Person-to-person or telephone interviews with ATN clinical site staff and staff from their community partners will be audio-taped. | ||
| Component 3 | Notes from direct observation of the linkage to medical care process within sites will be taken. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Describe and evaluate community screening standards and practices. | 1 year | |
| Describe and evaluate the relationships of screening venues with care-providing venues. | 1 year | |
| Describe and evaluate referral and intake protocols. | 1 year | |
| Describe and evaluate care adherence support (including support from both clinical and non-clinical sources). | 1 year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Component 1: The object of study is a collection of documents on existing linkage-to-care protocols and does not constitute a population. Component 2: Ideally, a minimum of two clinical staff and/or case managers from each of 15 AMTU and a minimum of one staff member representing the AMTU's community partners/sites where linkage to care activities occur. Component 3- Structured Observations: Clinical site staff providing linkage to care counseling. Please note that patients are not part of this study population. See Section 5.3 and Section 10.0 for additional details.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| J. Dennis Fortenberry, MD | Adolescent Trials Network | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010-2970 | United States | ||
Not provided
| Label | URL |
|---|---|
| Adolescent Trials Network website | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Not provided
Not provided
Not provided
| Childrens Diagnostic&Treatment Center |
| Fort Lauderdale |
| Florida |
| 33316 |
| United States |
| University of Miami School of Medicine | Miami | Florida | 33101 | United States |
| Mount Sinai Medical Center | Manhattan | New York | 10128 | United States |
| Montefiore Medical Center | The Bronx | New York | 10467 | United States |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | United States |
| St. Jude Childrens Research Hospital | Memphis | Tennessee | 38105 | United States |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |